Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma Inc ADR (NY: AMAM )

10.13 UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ambrx Biopharma Inc ADR

< Previous 1 2 3 4 5 6 Next >
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason
Via Benzinga
Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial
Via Benzinga
Earnings Scheduled For April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million. 
Via Benzinga
Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday's Mid-Day Session
Gainers FedNat Holding Company (NASDAQ: FNHC) shares rose 78.9% to $0.93 after jumping 48% on Friday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  During Monday's session, 38 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's morning session, 34 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Illumina (NASDAQ:ILMN) was the biggest company... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial
Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented favorable safety and efficacy data from its ongoing ACE-... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low
Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment
Photo by Dimitri Karastelev on Unsplash Pasithea Therapeutics (NASDAQ: KTTA), a Florida-based biotechnology company, strives to discover new treatments for mental and neurological... 
Via Benzinga
These 3 New Biotechs Have Differentiated Platforms, Technology: BofA
Following the expiry of IPO quiet periods for the recently listed Ambrx Biopharma Inc. (NASDAQ: 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback... 
Via Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
54 Biggest Movers From Yesterday
Gainers Sight Sciences, Inc. (NASDAQ: SGHT) shares jumped 39.6% to settle at $33.50 on Thursday as the company priced its IPO at $24 per share. Cinedigm Corp. (NASDAQ: CIDM)... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Bar... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.